(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 140.66% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.33%.
Syndax Pharmaceuticals's revenue in 2025 is $23,680,000.On average, 4 Wall Street analysts forecast SNDX's revenue for 2025 to be $6,431,183,695, with the lowest SNDX revenue forecast at $4,929,197,776, and the highest SNDX revenue forecast at $8,043,280,839. On average, 4 Wall Street analysts forecast SNDX's revenue for 2026 to be $15,205,413,810, with the lowest SNDX revenue forecast at $11,316,509,031, and the highest SNDX revenue forecast at $18,397,176,901.
In 2027, SNDX is forecast to generate $29,276,854,059 in revenue, with the lowest revenue forecast at $19,709,048,909 and the highest revenue forecast at $40,242,211,513.